Brief: Sanofi And Regeneron's Dupixent Approved In Japan For Children With Bronchial Asthma
23/12/2025 06:02
Dec 23 (Reuters) - Sanofi SA SASY.PA: SANOFI AND REGENERON’S DUPIXENT APPROVED IN JAPAN FOR CHILDREN AGED 6 TO 11 YEARS WITH BRONCHIAL ASTHMA APPROVAL BASED ON GLOBAL PHASE 3 PROGRAM IN CHILDREN DEMONSTRATING DUPIXENT SIGNIFICANTLY REDUCED EXACERBATIONS DUPIXENT REDUCES ASTHMA EXACERBATIONS BY 54%-65% Source text: ID:nGNEbs95KF Further company coverage: SASY.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Regeneron Pharmaceuticals
See all newsLilly, Regeneron selected for US program to review new manufacturing plants faster (updated)
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
Brief: Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities - CNBC
Brief: Cemdisiran Regulatory Submissions Accepted For Review By FDA And EMA For The Treatment Of Generalized Myasthenia Gravis (Gmg)
AbbVie sharpens immunology focus with $10.9 billion Apogee deal (updated)